Connect Biopharma (CNTB) vs Elicio Therapeutics (ELTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Connect Biopharma (CNTB) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 80.6% versus a loss of 82.8%. Over five years, CNTB leads with a -86.9% price change compared with -96.1% for ELTX. Elicio Therapeutics is the larger company by market cap ($41.0 million vs $38.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | ELTX |
|---|---|---|
| Share price | $0.59 | $1.45 |
| Market cap | $38.05M | $41.05M |
| 1-day change | -6.08% | -3.33% |
| YTD return | -79.08% | -81.78% |
| 1-year return | -80.59% | -82.84% |
| 5-year return | -86.89% | -96.13% |
| EPS (TTM) | $-1.14 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $64.00K | — |
| Revenue growth (YoY) | -99.75% | — |
| Net income (latest FY) | $-55.48M | $-39.57M |
| Operating margin | -90740.63% | — |
| Net margin | -86687.50% | — |
| 52-week high | $3.82 | $16.00 |
| 52-week low | $0.55 | $1.25 |
| Distance from 52-week high | -84.55% | -90.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +896.61% | +842.76% |
| Average volume | 3.98M | 324.71K |
| Shares outstanding | 64.49M | 28.31M |
| Employees | 64 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
CNTB vs ELTX FAQ
Which is bigger, Connect Biopharma or Elicio Therapeutics?
Elicio Therapeutics (ELTX) is larger, with a market capitalization of $41.05M compared with $38.05M for Connect Biopharma (CNTB).
Which stock has performed better over the past year, CNTB or ELTX?
CNTB returned -80.59% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Elicio Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.